No Data
UniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
Raymond James Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $20
UniQure Price Target Announced at $20.00/Share by Raymond James
UniQure (NASDAQ:QURE) Shareholders Are up 28% This Past Week, but Still in the Red Over the Last Five Years
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
FDA Grants Orphan Drug Status to UniQure's AMT-191, Aiming to Treat Fabry Disease
No Data
No Data